Journal ArticleDOI
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
David J. Hosking,C. E. D. Chilvers,C. Christiansen,Pernille Ravn,R. D. Wasnich,Philip D. Ross,Michael R. McClung,Ana Balske,D. E. Thompson,M. Daley,A. J. Yates +10 more
TLDR
Estrogen-replacement therapy prevents osteoporosis in postmenopausal women by inhibiting bone resorption, but the balance between its long-term risks and benefits remains unclear.Abstract:
Background Estrogen-replacement therapy prevents osteoporosis in postmenopausal women by inhibiting bone resorption, but the balance between its long-term risks and benefits remains unclear. Whether other antiresorptive therapies can prevent osteoporosis in these women is also not clear. Methods We studied the effect of 2.5 mg or 5 mg of alendronate per day or placebo on bone mineral density in 1174 postmenopausal women under 60 years of age. An additional 435 women who were prepared to receive a combination of estrogen and progestin were randomly assigned to one of the above treatments or open-label estrogen–progestin. The main outcome measure was the change in bone mineral density of the lumbar spine, hip, distal forearm, and total body measured annually for two years by dual-energy x-ray absorptiometry. Results The women who received placebo lost bone mineral density at all measured sites, whereas the women treated with 5 mg of alendronate daily had a mean (±SE) increase in bone mineral density of 3.5±...read more
Citations
More filters
Journal ArticleDOI
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
Steven R. Cummings,Dennis M. Black,Desmond E. Thompson,William B. Applegate,Elizabeth Barrett-Connor,Thomas Musliner,Lisa Palermo,Ronald J. Prineas,Susan M. Rubin,Jean Scott,Thomas M. Vogt,Robert B. Wallace,A. John Yates,Andrea Z. LaCroix +13 more
TL;DR: In women with low BMD but without vertebral fractures, 4 years of alendronate safely increased BMD and decreased the risk of first vertebral deformity.
Journal ArticleDOI
A comparison of observational studies and randomized, controlled trials.
Kjell Benson,Arthur J. Hartz +1 more
TL;DR: Little evidence is found that estimates of treatment effects in observational studies reported after 1984 are either consistently larger than or qualitatively different from those obtained in randomized, controlled trials.
Journal ArticleDOI
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
Alexandra Papaioannou,Suzanne N Morin,Angela M. Cheung,Stephanie A. Atkinson,Jacques P. Brown,Sidney Feldman,David A. Hanley,Anthony B. Hodsman,Sophie A. Jamal,Stephanie M. Kaiser,Brent Kvern,Kerry Siminoski,William D. Leslie +12 more
TL;DR: There has been a paradigm shift in the prevention and treatment of osteoporosis and fractures, and the focus now is on preventing fragility fractures and their negative effects.
Journal ArticleDOI
Therapeutic approaches to bone diseases.
Gideon A. Rodan,T. John Martin +1 more
TL;DR: A better understanding of the biology of osteoclasts and osteoblasts is providing opportunities for developing therapeutics to treat diseases of bone, and promoting bone formation with growth factors or hormones is an approach that would be a valuable adjunct therapy for patients receiving inhibitors of bone resorption.
Journal ArticleDOI
Ten years' experience with alendronate for osteoporosis in postmenopausal women.
Henry G. Bone,David J. Hosking,Jean-Pierre Devogelaer,Joseph R. Tucci,Ronald Emkey,Richard P. Tonino,Jose Adolfo Rodriguez-Portales,Robert W. Downs,Jayanti Gupta,Arthur C. Santora,Uri A. Liberman +10 more
TL;DR: The therapeutic effects of alendronate were sustained, and the drug was well tolerated over a 10-year period, as measured by bone density and biochemical markers of bone remodeling.
References
More filters
Journal ArticleDOI
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Dennis M. Black,Steven R. Cummings,David B. Karpf,Jane A. Cauley,Desmond E. Thompson,Michael C. Nevitt,Douglas C. Bauer,Harry K. Genant,William L. Haskell,Robert Marcus,Susan M. Ott,James C. Torner,Sara A. Quandt,Theodore F. Reiss,Kristine E. Ensrud +14 more
TL;DR: Among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and substantially reduces the frequency of morphometric and clinical vertebra fractures, as well as other clinical fractures.
Journal ArticleDOI
Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis
Uri A. Liberman,Stuart R. Weiss,Johann Broll,Helmut W. Minne,Hui Quan,Norman H. Bell,Jose Adolfo Rodriguez-Portales,Robert W. Downs,Jan Dequeker,Murray J. Favus,Ego Seeman,Robert R. Recker,Thomas P. Capizzi,Arthur C. Santora,Antonio Lombardi,Raksha V. Shah,Laurence J. Hirsch,David B. Karpf +17 more
TL;DR: Daily treatment with alendronate progressively increases the bone mass in the spine, hip, and total body and reduces the incidence of vertebral fractures, the progression of vertebra deformities, and height loss in postmenopausal women with osteoporosis.
Journal ArticleDOI
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Graham A. Colditz,Susan E. Hankinson,David J. Hunter,Walter C. Willett,JoAnn E. Manson,Meir J. Stampfer,Charles H. Hennekens,Bernard Rosner,Frank E. Speizer +8 more
TL;DR: In this paper, the effect of adding progestins to estrogen therapy on the risk of breast cancer in postmenopausal women is investigated. But, the effect on the number of newly diagnosed invasive breast cancer cases was not quantified.
Journal ArticleDOI
Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease
Francine Grodstein,Meir J. Stampfer,JoAnn E. Manson,Graham A. Colditz,Walter C. Willett,Bernard Rosner,Frank E. Speizer,Charles H. Hennekens +7 more
TL;DR: In this paper, the authors examined the relation between cardiovascular disease and postmenopausal hormone therapy during up to 16 years of follow-up in 59,337 women from the Nurses' Health Study, who were 30 to 55 years of age at base line.
Journal ArticleDOI
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
Nelson B. Watts,S. T. Harris,Harry K. Genant,Richard D. Wasnich,Paul D. Miller,Rebecca D. Jackson,A.A. Licata,Philip D. Ross,G C Woodson rd,M. J. Yanover +9 more
TL;DR: A prospective, two-year, double-blind, placebo-controlled, multicenter study in 429 women who had one to four vertebral compression fractures plus radiographic evidence of osteopenia to determine the effects of etidronate in the treatment of postmenopausal osteoporosis.
Related Papers (5)
Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial
Bruce Ettinger,Dennis M. Black,Bruce H. Mitlak,Ronald Keith Knickerbocker,Thomas Nickelsen,Harry K. Genant,Claus Christiansen,Pierre D. Delmas,Jose R. Zanchetta,J. A. Stakkestad,Claus C. Glüer,Kathryn A. Krueger,Fredric J. Cohen,Stephen Eckert,Kristine E. Ensrud,Louis V. Avioli,Paul Lips,Steven R. Cummings +17 more